Revolutionizing HNSCC Treatment: Genexine’s GX-188E and GX-I7 Triple Combination Therapy Unveiled at 2023 ASCO Annual Meeting
Genexine’s Triple Combination Shows Promising Results in HPV-positive HNSCC Patients Introduction A recent phase 2 trial conducted by Genexine has shown exciting results in the treatment of HPV-positive Head and Neck Squamous Cell Carcinoma (HNSCC). The trial involved a triple combination of Genexine’s DNA vaccine GX-188E, its long-acting Interleukin-7 GX-I7, and Keytruda, which resulted in…